Eisai’s EMEA Ops To Supply Fycompa in U.S.

Eisai has received FDA approval for the U.S. supply of the epilepsy drug Fycompa (perampanel) from its EMEA Knowledge Centre based in Hatfield, UK. The Hatfield site will manufacture six different strengths of tablets for the U.S. market. Eisai recently constructed a new 2,900m² facility for the global packaging of potent compounds, which expands the current 7,800m² Hatfield site by nearly 40%.
 
Gary Hendler, president and chief executive officer of Eisai EMEA, said, “The FDA approval for the supply of our epilepsy drug perampanel is testament to the commitment we have made at our EMEA Knowledge Centre and the Hatfield manufacturing facility. The UK is a competitive location for advanced manufacturing and packaging and I am delighted that we are now able to export products developed and manufactured here in the UK to the U.S.”